ABAymen A. Bash

Aymen A. Bash

*This is an algorithmically generated author record based on publicly available information.

Aymen A. Bash has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug synthesis, separation, and identification of a di-stereoisomeric mixture of spiro-oxalidinonic derivatives of sorbinil by high-performance liquid chromatography

    by Esaim Fadhel Khalfa, Rawaa G. Abdullah, Qasim Jawad Al-Daami, Aymen Bash, Saba Abdulmunem Habeeb Al-Qaysi, Ghassan Jasim Mohammed, Widad Abd Al-Jabbar Mozzan

    A straightforward and sensitive method for high-performance liquid chromatography (HPLC) was created in order to separate and identify the di-stereoisomeric mixture of a spiro-oxalidinonic derivative of sorbinil. HPLC was carried out using a C18 reversed-phase column. The mobile phase used in the isocratic elution process was a 70:30 v/v combi¬nation of methanol and acetonitrile flowed at a rate of 2 mL/min. The procedure delivered the best result among the various attempts made. Two peaks were identified on the chromatogram, attributable to the two di-stereoisomers of the mixture analysed. Analogues of sorbinil, a powerful inhibitor of aldose reductase, have been synthesized and further tested on aldose reductase as mixtures of di-stereoisomers, exhibiting an IC50 in the order of the micromolar. The structure of the compounds was checked with nuclear magnetic resonance spectroscopy. The chemical shifts were expressed in ppm scale δ.

  • Novel anticancer mechanisms of JinYingZi-derived oleanolic acid against renal cell carcinoma: an in silico analysis

    by Ismael Obaidi, Fatimah Adnan Alzubaidi, Aymen A. Bash, Qayssar Joudah Fadheel, Hussam W. Al-Humadi, Junying Liu

    Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all estimated cases. Advanced RCC often carries poor prognosis due to its high metastases rate, the lack of early-warning signs, as well as its complex clinical manifestations and its resistance to chemotherapy. Ethnopharmacologically, Fructus Rosae laevigata (JinYingZi) has been employed by Chinese medicine to treat various urinary tract and gastrointestinal dis¬orders. This study aimed at performing a series of mechanistic analyses in order to unlock the anticancer potential of JinYingZi-derived bioactive components against RCC. Several network pharmacology tools were employed so as to analyse the drug-disease interactions. Our data revealed that more than 2,214 genes were dysregulated in RCC, whereas the JinYingZi-derived bioactive compounds modulated 347 genes. The intersecting between RCC and the bioactive compounds revealed 132 cross targets. Our results were further validated by conducting molecular docking, which revealed a stable association between oleanolic acid with each of the following targets: androgen receptor (AR), dipeptidyl peptidase (DPP), estradiol (ESR1), nitric oxide synthase 2 (NOS2), and cyclooxygenase-2 (PTGS2). Our approach is being used successfully in order to evaluate a panel of novel medicinal plant-derived bioactive com¬pounds, and may lead to the identification of safe and effective chemical scaffolds that could act as templates for drug discovery or yield potential drug candidates.